Compare Dyne Therapeutics Inc. Common Stock (DYN) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs UBS Group AG Registered Ordinary Shares — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while UBS Group AG Registered Ordinary Shares trades at $47.21 (market cap $147.14B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 51.4× Dyne Therapeutics Inc. Common Stock's market cap, and UBS Group AG Registered Ordinary Shares pays a 2.3% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and UBS Group AG Registered Ordinary Shares for 3 Days on average.
| DYN | UBS | |
|---|---|---|
Market Cap | $2.86B | $147.14B |
Volume | 3,341,579 | 1,589,541 |
Sector | Health | Financials |
52-Week High | $26.78 | $55.72 |
52-Week Low | $14.60 | $36.41 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $2.18B | $315.77B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
UBS trades at $47.85, showing minimal daily movement with a 0.06% gain. The technical picture is bearish with mixed earnings performance - beating estimates in Q1 2026 but missing in Q4 2025 and Q2 2026. Analyst sentiment leans positive with 55% buy ratings, though the consensus price target of $23.57 sits well below current levels. Recent news highlights UBS's strategic focus on US expansion and ongoing integration challenges.
The outlook remains cautious given the bearish technical signals and valuation concerns. Investment opportunity exists in the company's improving profitability and revenue growth trajectory, but risks include integration challenges from recent acquisitions and exposure to European debt market volatility. The significant gap between current price and analyst targets warrants careful consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
